Brief: Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Holding AG

18/12/2023 11:53

Dec 18 (Reuters) - Oculis Holding AG  CR5.F :
    * OCULIS ANNOUNCES FIRST PATIENT FIRST VISIT IN PHASE 3
DIAMOND-1
TRIAL OF OCS-01 EYE DROP IN DIABETIC MACULAR EDEMA
    * OCULIS HOLDING AG - SECOND 52 WEEKS PHASE 3 TRIAL OF
OCS-01 IN
DME, DIAMOND-2, IS ANTICIPATED TO START IN Q1 2024
    * OCULIS-DIAMOND-1 PHASE 3 TRIAL, ASSESSING EFFICACY &
SAFETY OF
OCS-01 EYE DROPS FOLLOWING 52 WEEKS OF TREATMENT IN DME
PATIENTS, INITIATED AS PLANNED
    * OCULIS-STAGE 1 RESULTS SHOWED SUPERIORITY OF OCS-01 EYE
DROPS
VERSUS VEHICLE WITH ROBUST STATISTICAL SIGNIFICANCE, NO
UNEXPECTED ADVERSE EVENTS OBSERVED
    * OCULIS HOLDING AG - OCS-01 ACHIEVED PRIMARY ENDPOINT

Source text for Eikon:  ID:nGNX6PN7ZB 
Further company coverage:  CR5.F 

 ((Reuters.Briefs@thomsonreuters.com;))